Author Archive | Raynovich Rod

ASCO Week News Summaries

follow url Here are some other good ASCO News sources from MedAdNews: PharmAviary provides a round up of the industry tweets of the week. Chris Truelove, editor in chief of Med Ad News and R&D Directions, scours the healthcare blogosphere to bring you a digestible summary of the big trends and issues that have everyone talking. Updates from #ASCO, and back […]

Continue Reading 0

Very Limited ASCO Boost For Biotechnology Stocks – Update 1 PCYC

go to link A Biopharma Stock We Missed-Pharmacyclics (PCYC $38.21) up 9.89% today It is unbelievable that we missed the huge move in PCYC up 157% YTD with a one year range of 7.63 to 38.56. The market cap is $2.63B. The Company has a robust pipeline of products led by Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor […]

Continue Reading 0

Rayno Life Science Portfolio Gets ASCO Boost With Antibody Drug Conjugates

buy accutane uk online Antibody Drug Conjugates Make Progress for Cancer Therapy- Immunogen and Seattle Genetics Many of our focus stocks were up today helped by a late day rally that brought the NASDAQ up 0.46% at the close. Major biotechnology ETF’s (IBB,XBI) also recovered with some green by the end of the day.The Rayno Life Science Portfolio was […]

Continue Reading 0

MO Gang Taking Profits With Risk OFF

Jobs Number Spooks Traders-Dow Erases Gains for the Year Large cap biotechnology and MO growth stocks are taking a big hit today as hedgies take profits. Many of these stocks are still up YTD but profits are quickly eroding. Stocks to watch in technology, retail and biotechnology are :Intuitive Surgical ISRG ($507) down 3%,Lululemon LULU ($70) down 3.5%, […]

Continue Reading 0

Risk Still OFF with Euro Malaise

Look for biotechnology intermediate top as we approach ASCO next week. Market is now driven by hedgies and big funds.IBB  ($123.90) double top with YTD high of  $126.90 Mid cap biotech index off 1.7%. DX and tools also very weak. S&P unchanged from one year ago.

Continue Reading 0

Notes from B Riley 13th Annual Investor Conference: CEMI,VRML

There were some excellent small cap companies presenting at the B. Riley Investor Conference in Santa Monica this week. Five tracks covered companies in healthcare, technology and energy, consumer/telecom, software and services and internet and media. Our focus within healthcare is biotechnology, tools and clinical diagnostics. Micro-Cap Plays in Clinical Diagnostics Chembio (CEMI.PK  $0.52)  Market […]

Continue Reading 0

Todays’ Sell-Off Finally Hits Resilient Biotech Stocks

Facebook Hype Effect-Sell MO Stocks? Many of the favorite momentum stocks are being hit with profit taking today including large cap biopharmaceutical stocks. With the NASDAQ down 0.8% at 2850,  we see a lot of countertrends like gold up $39.70 off recent lows to $1576 accompanied by a big rally in silver and other metal stocks […]

Continue Reading 0

Biotech Sector Avoids Nasty Correction and Hits New Highs

Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April compared to the S&P […]

Continue Reading 0

Rayno Life Science -Biomarkers: BGMD,VRML

Biomarker MicroCap Face-Off: BGMD vs VRML Vermillion announced Q1 Results today today with OVA1 revenues of $312K of which $114 k was licensing revenues from their testing partner Quest Diagnostics Inc.(DGX $57). Operating expenses were down to $2.4M compared to$4.8M in the same period a year ago for a Q1 Net Loss of  $1.8M or […]

Continue Reading 0

Rayno Life Science: DX and Tools Update ALR 5/11/12

More Bad News on Alere The second shoe has dropped on Alere (ALR $19) with the stock off 15% as the FDA inspection news regarding manufacturing and quality at the “Biosite”facility.Leerink Swann downgraded the stock to “Market Perform” after trying to support the stock earlier but there is downside risk with potential product recalls and […]

Continue Reading 0